Former Merck, Purdue Pharma Exec Timney Named Medicines Company CEO

Mark Timney has been appointed CEO of The Medicines Company (NASDAQ: [[ticker:MDCO]]), effective immediately. Timney is also joining the Parsippany, NJ, company’s board of directors. Timney succeeds Clive Meanwell, who is now serving as chief innovation officer. Timney was CEO of Purdue Pharmaceuticals from 2014 to 2017. Before that, he spent six years at Merck (NYSE: [[ticker:MRK]]) in a number of senior roles. In the past year, The Medicines Company has sold its infectious disease assets and turned its focus to inclisiran, a cholesterol-lowering drug in Phase 3 clinical testing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan